• Skip to primary navigation
  • Skip to main content
  • Skip to footer
SNI Global

SNI Global

The Soy Nutrition Institute provides information, research, and discussion about the benefits of soy to your health.

  • Research
  • News & Resources
    • News
    • Science Perspectives Blog
    • Health Professional Hub
    • Fact Sheets
  • Soy Foods
    • Soybean Oil
    • High Oleic Soybean Oil
    • Soy Isoflavones
    • Soy Protein
    • U.S. Grown Soy
  • About
    • About SNI Global
    • Board Members & Staff
    • Members
    • Scientific Advisory Board
    • Join SNI Global
  • Stay in the know

Soy and Breast Cancer: What Does the Research Say?

Questions about soy and breast cancer often center on isoflavones, compounds commonly called phytoestrogens. Here’s what human research tells us about soy, estrogen, breast cancer risk, and eating soy after a breast cancer diagnosis.

Soy foods provide high-quality protein, essential fatty acids, and a variety of vitamins and minerals.[1-3] They are also uniquely rich sources of isoflavones, naturally occurring plant compounds commonly classified as phytoestrogens.[4,8]

That “phytoestrogen” label has contributed to concerns that soy might function like estrogen in the body, thereby increasing breast cancer risk and adversely affecting the prognosis of women with breast cancer. However, clinical research provides a reassuring picture. The results of human intervention studies support the safety of soy foods for women, including women living with breast cancer. Furthermore, observational studies indicate that eating soy after a breast cancer diagnosis is associated with better outcomes. Evidence also suggests that soy consumption can reduce the risk of developing breast cancer in the first place, although study results are somewhat inconsistent, and it may be that the most marked reduction in risk requires consuming soy during childhood and/or adolescence.[28,29,34-36]

No. Soy does not contain human estrogen.

Soybeans contain isoflavones, plant compounds commonly classified as phytoestrogens because they can interact with estrogen receptors in the body.[4,8,13] However, isoflavones differ chemically from estrogen, bind to estrogen receptors differently, and affect tissues much differently.

These distinctions are important. Calling isoflavones “phytoestrogens” does not mean that eating soy produces the same effects in the body as exposure to estrogen.

Isoflavones are commonly classified as phytoestrogens because laboratory tests have shown that they can interact with estrogen receptors.[8,13]

Researchers have identified two types of estrogen receptors, ER-alpha and ER-beta. [11] Isoflavones preferentially bind to ER-beta.[12,13] The two receptors can produce different, and sometimes opposing, physiological effects when bound and activated.[14-16]

This difference helps explain why simply labeling a substance “estrogenic” does not necessarily predict what it will do in a particular tissue.

Some compounds that interact with estrogen receptors can have estrogen-like effects in one tissue and little effect or an opposing effect in another. These compounds are known as selective estrogen receptor modulators, or SERMs. Isoflavones have been described as natural or partial SERMs.[17-20]

Clinical research shows soy does not produce the hormonal effects that one might expect if it acted like human estrogen.

In men, a statistical analysis (meta-analysis) of clinical studies found that neither soy nor isoflavone intake affects circulating testosterone or estrogen levels.[21]

Researchers have also studied postmenopausal women, a group that theoretically is most sensitive to the claimed estrogen-like effects of isoflavones. In contrast to the effects of estrogen, results from a 2025 systematic review and meta-analysis of randomized controlled trials found that isoflavone intake did not affect estrogen levels, endometrial thickness, vaginal maturation index, or follicle-stimulating hormone levels.[22] All of these outcomes are affected by estrogen.

Randomized controlled trials (human intervention studies) show that soy does not affect established markers of breast cancer risk.

Two markers that researchers use when studying breast cancer risk are breast tissue density and breast cell proliferation. Greater breast density and increased cell proliferation are associated with increased breast cancer risk.[23-27]

A review of clinical research that included 14 intervention studies found that neither soy protein, soy foods, nor isoflavone supplements increased breast tissue density. Additionally, none of the 6 studies that evaluated breast cell proliferation found an effect of soy or isoflavones. [28]

Importantly, these clinical studies involved healthy women, women at increased risk for breast cancer, and women living with breast cancer.[28]

Together, this clinical evidence supports the safety of soy consumption regardless of breast cancer status.

Possibly, but the evidence is not definitive.

Observational studies have generally associated higher soy and isoflavone intake with lower breast cancer risk. For example, a 2023 dose-response meta-analysis of seven cohort studies found that each additional 10 milligrams of isoflavones consumed per day was associated with a 3.2% or 6.8% lower risk of breast cancer, depending on the statistical model used.[29]  

However, while observational studies can identify associations, they cannot establish that soy itself caused the lower risk.

Studying this relationship in the United States and other populations where soy consumption is relatively low presents challenges. Average isoflavone intake in the United States and Europe is fewer than 3 milligrams per day, compared with approximately 30 to 50 milligrams among people consuming a traditional Japanese diet.[5-7,30]

There is another reason for caution in interpreting the protective association. Treatments known to reduce breast cancer risk tend to decrease mammographic density or breast cell proliferation, whereas soy has not been shown to affect these markers.[28,31-33]

Researchers continue to investigate whether other factors, including when soy is consumed during life, might help explain the observational findings.

It may, but this contention remains an intriguing hypothesis rather than a settled conclusion.

Researchers have proposed that eating soy during childhood or adolescence affects breast tissue development in ways that decrease breast cancer risk later in life.

Observational evidence provides support for this “early soy intake hypothesis.” Observational research examining early soy consumption indicates that approximately one (or slightly more than one) serving of soy foods per day is associated with lower breast cancer risk in adulthood.[34]

More research is needed to determine whether early soy consumption itself is responsible for the reduced risk.

Current human evidence supports the safety of soy consumption for women living with breast cancer, including women undergoing treatment.[28]

Clinical studies examining breast tissue density and breast cell proliferation have found no adverse effects from consuming soy foods, soy protein, or isoflavones in women with breast cancer.[28]

Evidence raising concern came almost exclusively from animal experiments, including studies involving mice implanted with estrogen receptor-positive human breast cancer cells.[9,10] These experiments helped generate hypotheses, but findings from animal models do not necessarily predict what happens when people eat soy foods.

Human clinical and observational evidence does not support the concern that typical soy consumption worsens breast cancer outcomes.[28,35,36]

People undergoing breast cancer treatment should discuss individual dietary concerns with their health care team, particularly when considering substantial dietary changes.

Observational evidence indicates that soy consumption after a breast cancer diagnosis is associated with favorable outcomes.

In its 2022 nutrition and physical activity guideline for cancer survivors, the American Cancer Society concluded that postdiagnosis soy isoflavone intake is associated with a lower risk of breast cancer recurrence.[35]

A 2023 systematic review and meta-analysis conducted by the World Cancer Research Fund International and American Institute for Cancer Research identified soy food intake as one of several dietary and lifestyle factors that may be associated with lower mortality among people with breast cancer.[36]

Because these findings are based largely on observational research, they do not establish that soy itself improves survival or prevents recurrence. Soy should not be viewed as a treatment for breast cancer.

The findings do, however, provide additional evidence that women do not need to avoid soy foods simply because they have been diagnosed with breast cancer.

The amount of soy associated with favorable breast cancer outcomes is approximately two to three servings daily. [28]

Clinical studies examining markers of breast cancer risk have typically used approximately 50 to 100 milligrams of isoflavones per day. That is roughly the amount provided by two to four servings of traditional Asian soy foods.[28]

In observational studies examining soy intake after a breast cancer diagnosis, participants in the highest intake groups typically consumed isoflavone amounts equivalent to approximately two to three servings of soy foods per day.[28]

One serving (e.g., 1 cup soymilk, 3 oz. tofu) provides approximately 25 milligrams of isoflavones.[4] Different soy foods deliver varied amounts of isoflavones.

Current human evidence supports the safety of soy foods.

Clinical research shows soy does not adversely affect breast tissue density or breast cell proliferation, two markers of breast cancer risk. [23-28] Concerns about soy and breast cancer have been driven largely by animal studies rather than evidence of harm in human clinical and observational studies, which carry much greater weight in the scientific community.[9,10]

Observational research also suggests that eating soy after a breast cancer diagnosis may be associated with a lower risk of recurrence and mortality.[28,35,36] Whether soy reduces the initial risk of developing breast cancer is less certain, although observational research suggests a possible protective association.[29] Research is continuing, including studies examining whether soy consumption during childhood or adolescence could influence risk later in life.[34] Based on the clinical and observational evidence available today, there is no reason to avoid soy foods because of concerns about breast cancer.

  1. Hughes GJ, Ryan DJ, Mukherjea R, Schasteen CS. Protein digestibility-corrected amino acid scores (PDCAAS) for soy protein isolates and concentrate: Criteria for evaluation. J Agric Food Chem. 2011;59:12707-12.
  2. Abdelghany AM, Zhang S, Azam M, Shaibu AS, Feng Y, Qi J, et al. Natural variation in fatty acid composition of diverse world soybean germplasms grown in China. Agronomy. 2020;10.
  3. Messina MJ. Legumes and soybeans: Overview of their nutritional profiles and health effects. Am J Clin Nutr. 1999;70:439S-50S.
  4. Bhagwat S, Haytowitz DB. USDA Database for the Isoflavone Content of Selected Foods, Release 2.1. U.S. Department of Agriculture, Agricultural Research Service. 2015.
  5. Murai U, Sawada N, Charvat H, Inoue M, Yasuda N, Yamagishi K, et al. Soy product intake and risk of incident disabling dementia: The JPHC Disabling Dementia Study. Eur J Nutr. 2022;61:4045-57.
  6. Zamora-Ros R, Knaze V, Lujan-Barroso L, Kuhnle GG, Mulligan AA, Touillaud M, et al. Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition 24-hour dietary recall cohort. Eur J Clin Nutr. 2012;66:932-41.
  7. Bai W, Wang C, Ren C. Intakes of total and individual flavonoids by U.S. adults. Int J Food Sci Nutr. 2014;65:9-20.
  8. Messina M, Barnes S, Setchell KD. Perspective: Isoflavones — intriguing molecules but much remains to be learned about these soybean constituents. Adv Nutr. 2025;16:100418.
  9. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58:3833-8.
  10. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: A complex story. Inflammopharmacology. 2008;16:219-26.
  11. Biason-Lauber A, Lang-Muritano M. Estrogens: Two nuclear receptors, multiple possibilities, Mol Cell Endocrinol. 2022;554:111710.
  12. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells, Toxicol Sci. 2004;80:14-25.
  1. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252-63.
  2. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64:423-8.
  3. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM. Oestrogen receptor beta: What it means for patients with breast cancer. Lancet Oncol. 2004;5:174-81.
  4. Mal R, Magner A, David J, Datta J, Vallabhaneni M, Kassem M, et al. Estrogen receptor beta (ERbeta): A ligand activated tumor suppressor. Front Oncol. 2020;10:587386.
  5. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids. 2000;65:227-51.
  6. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med. 2008;74:1656-65.
  7. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142-54.
  8. Brzezinski A, Debi A. Phytoestrogens: The “natural” selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol. 1999;85:47-51.
  9. Reed KE, Camargo J, Hamilton-Reeves J, Kurzer M, Messina M. Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis of clinical studies. Reprod Toxicol. 2021;100:60-7.
  10. Viscardi G, Back S, Ahmed A, Yang S, Mejia SB, Zurbau A, et al. Effect of soy isoflavones on measures of estrogenicity: A systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2025;16:100327.
  11. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6:798-808.
  12. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227-36.
  13. Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022;66:62-8.
  14. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers. 2021;13.
  15. Tomasetti C, Poling J, Roberts NJ, London NR Jr., Pittman ME, Haffner MC, et al. Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. Proc Natl Acad Sci U S A. 2019;116:20482-8.
  16. Messina M, Nechuta S. A review of the clinical and epidemiologic evidence relevant to the impact of postdiagnosis isoflavone intake on breast cancer outcomes. Curr Nutr Rep. 2025;14:50.
  17. Yang J, Shen H, Mi M, Qin Y. Isoflavone consumption and risk of breast cancer: An updated systematic review with meta-analysis of observational studies. Nutrients. 2023;15.
  18. Messina MJ, Messina V, Nagata C. Perspective: Observational studies involving low-soy intake populations have limited ability for providing insight into the health effects of soybean isoflavones. Adv Nutr. 2024;15:100210.
  19. Engmann NJ, Scott CG, Jensen MR, Ma L, Brandt KR, Mahmoudzadeh AP, et al. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomarkers Prev. 2017;26:930-7.
  20. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95:779-90.
  21. Takagi K, Ishida T, Miki Y, Hirakawa H, Kakugawa Y, Amano G, et al. Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment. Br J Cancer. 2013;109:100-8.
  22. Messina M, Duncan AM. Soy intake during childhood and/or adolescence and adult breast cancer: An examination of the early soy intake hypothesis. Nutrients. 2026;18.
  23. Rock CL, Thomson CA, Sullivan KR, Howe CL, Kushi LH, Caan BJ, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022;72:230-62.
  24. Becerra-Tomas N, Balducci K, Abar L, Aune D, Cariolou M, Greenwood DC, et al. Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme systematic literature review and meta-analysis. Int J Cancer. 2023;152:616-34.

Soy and Breast Cancer FAQs
Soy Connection 32.4: The Impact of Nutrition on Breast Cancer Recurrence and Survival

Empowering Health: Exploring the Nexus of Diet and Soy in Breast Cancer Recurrence

In this 80-minute webinar titled “Empowering Health: Exploring the Nexus of Diet and Soy in Breast Cancer Recurrence”, esteemed experts Lawrence H. Kushi, ScD, Mark Messina, PhD, MS, and Karen Collins, MS, RDN, CDN, FAND, summarize the latest research on soy and breast cancer and translate the findings to equip health professionals with the information needed to best counsel clients and patients. The webinar concludes with an insightful Q&A session, including the following questions answered by the speaker panel:

  • Were genetic factors accounted for in any of the studies shared during the webinar?
  • Is there any research discussing the differences between whole food forms of soy and processed food forms of soy, like soy protein isolate?
  • What are your thoughts on recommending ER+ breast cancer patients avoid isolated soy protein/soy protein isolate, but other forms of soy are okay?
  • For patients who have a genetic history and are at risk for getting breast cancer, are there specific dietary recommendations we can provide to help them lower their risk of getting breast cancer?
  • A lot of the studies covered evaluated diet around diagnosis, but are there any studies where they look at diet during treatment, or change in dietary patterns?
  • Is there any research you could share about soy and triple-negative breast cancer?
  • Why are breast cancer patients more susceptible to coronary artery disease?

ENTER YOUR EMAIL TO WATCH NOW ON DEMAND

John
Smith
johnsmith@example.com

This page is supported by SNI Global and U.S. Soy.

Health & Nutrition News About Soy

Get the dish on trending topics, insights, & soy research from industry experts delivered to your inbox.

Name(Required)
Consent(Required)

Footer

Organization

  • Research
  • Government Affairs
  • About
  • Staff & Board
  • Members
  • Scientific Advisory Board
  • Join SNI Global
  • Contact

News & Resources

  • Science Perspectives Blog
  • Expert Authors
  • News Releases
  • Fact Sheets
  • Videos & Webinars
  • Health Professional Guide

Soyfoods

  • Soybean Oil
  • High Oleic Soybean Oil
  • Soy Protein
  • Soy Isoflavones
  • U.S. Grown Soy
  • Recipes

Connect With Us

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube

Copyright © 2026 Soy Nutrition Institute Global · Privacy Policy · Accessibility Statement · Cookie Policy